PL3241558T3 - Wysoce rozpuszczalne leptyny - Google Patents

Wysoce rozpuszczalne leptyny

Info

Publication number
PL3241558T3
PL3241558T3 PL17163203T PL17163203T PL3241558T3 PL 3241558 T3 PL3241558 T3 PL 3241558T3 PL 17163203 T PL17163203 T PL 17163203T PL 17163203 T PL17163203 T PL 17163203T PL 3241558 T3 PL3241558 T3 PL 3241558T3
Authority
PL
Poland
Prior art keywords
leptins
highly soluble
soluble
highly
soluble leptins
Prior art date
Application number
PL17163203T
Other languages
English (en)
Inventor
Mary Erickson
Original Assignee
Aegerion Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aegerion Pharmaceuticals, Inc. filed Critical Aegerion Pharmaceuticals, Inc.
Publication of PL3241558T3 publication Critical patent/PL3241558T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/5759Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2264Obesity-gene products, e.g. leptin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17163203T 2010-09-28 2011-09-28 Wysoce rozpuszczalne leptyny PL3241558T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38740210P 2010-09-28 2010-09-28
US42209110P 2010-12-10 2010-12-10
PCT/US2011/053774 WO2012050925A2 (en) 2010-09-28 2011-09-28 Highly soluble leptins
EP11833075.2A EP2621515B1 (en) 2010-09-28 2011-09-28 A chimeric seal-human leptin polypeptide with increased solubility
EP17163203.7A EP3241558B1 (en) 2010-09-28 2011-09-28 Highly soluble leptins

Publications (1)

Publication Number Publication Date
PL3241558T3 true PL3241558T3 (pl) 2021-08-30

Family

ID=45938879

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17163203T PL3241558T3 (pl) 2010-09-28 2011-09-28 Wysoce rozpuszczalne leptyny

Country Status (14)

Country Link
US (6) US20130203661A1 (pl)
EP (4) EP2621519B1 (pl)
JP (5) JP2014502252A (pl)
CN (2) CN103403019B (pl)
BR (3) BR112013007388B1 (pl)
CA (3) CA2813038C (pl)
CY (2) CY1119023T1 (pl)
DK (3) DK3241558T3 (pl)
EA (2) EA024507B1 (pl)
ES (3) ES2873253T3 (pl)
MX (2) MX351128B (pl)
PL (1) PL3241558T3 (pl)
PT (2) PT2621515T (pl)
WO (2) WO2012050925A2 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201809437T4 (tr) 2010-07-09 2018-07-23 Affibody Ab Polipeptitler.
DK3241558T3 (da) * 2010-09-28 2021-04-26 Aegerion Pharmaceuticals Inc Højopløselige leptiner
JP6040464B2 (ja) * 2011-07-08 2016-12-07 アエゲリオン・ファーマシューティカルズ・インコーポレイテッドAegerion Pharmaceuticals, Inc. 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
WO2013148966A1 (en) * 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
WO2014048977A1 (en) * 2012-09-25 2014-04-03 Affibody Ab Albumin binding polzpeptide
CN105209054A (zh) 2013-04-18 2015-12-30 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
WO2014204816A2 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
EP3038642A4 (en) 2013-08-30 2017-01-18 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015070060A1 (en) 2013-11-11 2015-05-14 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10167322B2 (en) 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
ES2887370T3 (es) 2014-09-04 2021-12-22 Novo Nordisk As Nuevo agonista del receptor de amilina y calcitonina
CA2963989A1 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
EP3209320B1 (en) 2014-10-22 2023-03-08 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
ES2886576T3 (es) 2015-08-05 2021-12-20 Shaanxi Micot Tech Limited Company Compuesto de múltiples dianas con actividad anticoagulante y antiplaquetaria, método de preparación para el mismo y uso del mismo
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
MX2018002514A (es) 2015-09-22 2018-08-15 Univ California Citotoxinas modificadas y su uso terapeutico.
AU2016332352A1 (en) 2015-10-02 2018-04-12 Memorial Sloan-Kettering Cancer Center Small molecules blocking histone reader domains
BR112019004715A2 (pt) 2016-09-12 2019-07-16 Aegerion Pharmaceuticals Inc métodos para detectar anticorpos neutralizantes anti-leptina
CN118184777A (zh) * 2017-01-30 2024-06-14 亚力兄制药公司 单价抗备解素抗体及抗体片段
EP3773461A4 (en) * 2018-04-13 2022-02-09 Massachusetts Institute of Technology MODIFIED TREATMENTS FOR HAIR REPAIR AND LASTING COLOR RETENTION
EP4405494A2 (en) * 2021-09-24 2024-07-31 The UAB Research Foundation Control of subunit stoichiometry in single-chain msp nanopores

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4572208A (en) 1983-06-29 1986-02-25 Utah Medical Products, Inc. Metabolic gas monitoring apparatus and method
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
FI78231C (fi) 1984-11-21 1989-07-10 Instrumentarium Oy Maetanordning foer metaboliska storheter anslutbar till en respirator.
US4695463A (en) 1985-05-24 1987-09-22 Warner-Lambert Company Delivery system for active ingredients and preparation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
GEP20002145B (en) 1989-10-16 2000-06-25 Amgen Inc Us Stem Cell Factor
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
CA2107553C (en) 1991-04-05 2001-07-31 Nancy Lin Monoclonal antibodies to stem cell factor receptors
NZ244778A (en) 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5574133A (en) 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5563243A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5567803A (en) 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
WO1996023815A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Ob gene product antibodies
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5594104A (en) 1995-01-31 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5563245A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
CA2211656A1 (en) 1995-01-31 1996-08-08 Margret B. Basinski Anti-obesity proteins
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5563244A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
WO1996023515A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
US5525705A (en) 1995-01-31 1996-06-11 Eli Lilly And Company Anti-obesity proteins
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5567678A (en) 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5569744A (en) 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5594101A (en) 1995-03-03 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5719266A (en) 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
EP0736599A3 (en) 1995-04-03 1996-12-11 Takeda Chemical Industries Ltd The rat obesity gene, its gene product and its production
AU5539596A (en) 1995-04-06 1996-10-23 Amylin Pharmaceuticals, Inc. Anti-obesity agents
US5614379A (en) 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
US5840517A (en) * 1995-04-26 1998-11-24 Eli Lilly And Company Process for preparing obesity protein analogs
EP0741187A2 (en) 1995-05-05 1996-11-06 F. Hoffmann-La Roche Ag Recombinant obese (Ob) proteins
GB9509164D0 (en) 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
AU5737696A (en) 1995-05-08 1996-11-29 Chiron Corporation Nucleic acids for treating obesity
EP0744408A3 (en) 1995-05-26 1997-01-02 Eli Lilly And Company Rhesus ob protein and DNA
WO1996040912A1 (en) 1995-06-07 1996-12-19 Amgen Inc. Ob protein compositions and method
US5581005A (en) 1995-06-16 1996-12-03 The Procter & Gamble Company Method for manufacturing cobalt catalysts
AU6284896A (en) 1995-06-22 1997-01-22 Eli Lilly And Company Obesity protein intermediates and their preparation and use
GB2302559B (en) 1995-06-23 1998-06-03 Draftex Ind Ltd Opening arrangements and methods for closure members
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
PL324284A1 (en) * 1995-06-30 1998-05-11 Lilly Co Eli Methods of treating diabetes
JP4173913B2 (ja) 1995-08-17 2008-10-29 アムジエン・インコーポレーテツド Obタンパク質組成物を用いて血中脂質レベルを減少させ又は減少した血中脂質レベルを維持する方法
WO1997016550A1 (en) 1995-11-02 1997-05-09 Bristol-Myers Squibb Company Polypeptide fragments derived from the obese gene product
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
EP1285664B1 (en) 1995-11-22 2010-01-20 Amgen Inc. Methods of increasing lean tissue mass using OB protein compositions
AU1406497A (en) 1995-12-06 1997-06-27 Schering Corporation Mutational variants of mammalian ob gene proteins
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US5831017A (en) 1996-01-25 1998-11-03 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
US6013009A (en) 1996-03-12 2000-01-11 Karkanen; Kip Michael Walking/running heart rate monitoring system
AU2670897A (en) 1996-04-04 1997-10-29 Amgen, Inc. Fibulin pharmaceutical compositions and related methods
US6025324A (en) 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
PL330361A1 (en) 1996-06-06 1999-05-10 Smithkline Beecham Plc Leptin fragments (ob proteins)
US5922678A (en) 1996-06-28 1999-07-13 Eli Lilly And Company Methods for treating diabetes
JP2001501177A (ja) 1996-08-30 2001-01-30 アムジエン・インコーポレーテツド Obタンパク質受容体をアップレギュレートすることによりobタンパク質に対する個体の感受性を増加させる方法
WO1998012224A1 (en) 1996-09-20 1998-03-26 Hoechst Aktiengesellschaft Use of leptin antagonists for treating insulin resistance in type ii diabetes
AU4582597A (en) 1996-10-11 1998-05-11 Eli Lilly And Company Therapeutic proteins
AU5654998A (en) 1996-12-06 1998-06-29 F. Hoffmann-La Roche Ag Muteins of obese protein
EA004790B1 (ru) 1996-12-20 2004-08-26 Амген Инк. Композиции на основе слитого белка ов и способы их применения
US6309360B1 (en) 1997-03-17 2001-10-30 James R. Mault Respiratory calorimeter
WO1998041222A1 (en) * 1997-03-20 1998-09-24 Eli Lilly And Company Obesity protein formulations
AU2951797A (en) 1997-06-06 1998-12-21 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
ES2235336T3 (es) 1997-06-13 2005-07-01 Gryphon Therapeutics, Inc. Ligacion quimica nativa en fase solida de peptidos desprotegidos o protegidos en la cisteina n-terminal en solucion acuosa.
WO1999063614A1 (fr) 1998-05-29 1999-12-09 Catalysts & Chemicals Industries Co., Ltd. Procede servant a fabriquer une cellule photoelectrique et semiconducteur a l'oxyde pour cellule photoelectrique
DE69921486T2 (de) 1998-08-10 2006-02-02 Amgen Inc., Thousand Oaks Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
EP1118001A1 (en) 1998-10-02 2001-07-25 Amgen Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
DE60032331T2 (de) 1999-01-14 2007-06-21 Amylin Pharmaceuticals, Inc., San Diego Exendine zur glucagon suppression
ATE323766T1 (de) 1999-02-12 2006-05-15 Amgen Inc Glykosylierte leptinzusammensetzungen und zugehörige verfahren
US6475984B2 (en) * 1999-04-29 2002-11-05 The Nemours Foundation Administration of leptin
TW514510B (en) 1999-06-11 2002-12-21 Tanita Seisakusho Kk Method and apparatus for measuring distribution of body fat
US6468222B1 (en) 1999-08-02 2002-10-22 Healthetech, Inc. Metabolic calorimeter employing respiratory gas analysis
US6258932B1 (en) 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
CA2388417A1 (en) * 1999-09-22 2001-03-29 Genset Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
US6530886B1 (en) 1999-10-08 2003-03-11 Tanita Corporation Method and apparatus for measuring subcutaneous fat using ultrasonic wave
US7057015B1 (en) * 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
CN1423566A (zh) 1999-11-10 2003-06-11 武田药品工业株式会社 体重增加抑制剂
JP2001199887A (ja) 1999-11-10 2001-07-24 Takeda Chem Ind Ltd 体重増加抑制剤
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7157564B1 (en) 2000-04-06 2007-01-02 Affymetrix, Inc. Tag nucleic acids and probe arrays
EP1276756A4 (en) * 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
TW515705B (en) 2000-05-31 2003-01-01 Yamato Scale Co Ltd Visceral fat meter
US6492117B1 (en) 2000-07-12 2002-12-10 Gendaq Limited Zinc finger polypeptides capable of binding DNA quadruplexes
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6475158B1 (en) 2000-10-24 2002-11-05 Korr Medical Technologies, Inc. Calorimetry systems and methods
PL214862B1 (pl) 2001-10-22 2013-09-30 Amgen Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny
US6899892B2 (en) 2001-12-19 2005-05-31 Regents Of The University Of Minnesota Methods to reduce body fat
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
AU2003290563A1 (en) 2002-10-31 2004-05-25 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
CN1684990A (zh) 2002-11-01 2005-10-19 株式会社德山 聚合性组合物、其固化体的制造方法以及光学物品
WO2005028516A2 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
US20070203058A1 (en) * 2003-09-19 2007-08-30 Novo Nordisk A/S Novel Glp-1 Derivatives
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US8114958B2 (en) 2004-02-11 2012-02-14 Amylin Pharmaceuticals, Inc. Amylin family peptides
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
KR20070094909A (ko) 2004-12-02 2007-09-27 도만티스 리미티드 혈청 알부민 및 glp-1 또는 pyy를 표적으로 삼는이중특이성 도메인을 갖는 항체
US7898623B2 (en) 2005-07-04 2011-03-01 Semiconductor Energy Laboratory Co., Ltd. Display device, electronic device and method of driving display device
GB0524788D0 (en) * 2005-12-05 2006-01-11 Affibody Ab Polypeptides
EP1976873A2 (en) 2006-01-11 2008-10-08 Brystol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
EP1996617A2 (en) 2006-03-15 2008-12-03 Novo Nordisk A/S Amylin derivatives
WO2007114838A1 (en) 2006-03-31 2007-10-11 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
EP2035450A2 (en) 2006-05-26 2009-03-18 Amylin Pharmaceuticals, Inc. Composition and methods for treatment of congestive heart failure
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
CN101113175A (zh) * 2007-04-28 2008-01-30 中国科学院西北高原生物研究所 鼠兔家族瘦素蛋白及其cDNA序列
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
CN104710518A (zh) 2007-07-31 2015-06-17 阿菲博迪公司 新白蛋白结合组合物、方法及应用
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
US8598314B2 (en) * 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
EA201070609A1 (ru) 2007-11-14 2010-12-30 Амилин Фармасьютикалз, Инк. Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств
CN103694337B (zh) * 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
WO2010046357A1 (en) 2008-10-21 2010-04-29 Novo Nordisk A/S Amylin derivatives
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
AU2010206614B2 (en) 2009-01-22 2015-03-26 Keybioscience Ag Treatment for obesity
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
ES2676874T3 (es) * 2010-06-04 2018-07-25 Tiumbio Co., Ltd. Proteína de fusión que tiene actividad del factor VII
TR201809437T4 (tr) 2010-07-09 2018-07-23 Affibody Ab Polipeptitler.
MX345245B (es) 2010-09-28 2017-01-23 Amylin Pharmaceuticals Llc Polipeptidos manipulados que tienen duracion de accion incrementada.
DK3241558T3 (da) 2010-09-28 2021-04-26 Aegerion Pharmaceuticals Inc Højopløselige leptiner
JP6040464B2 (ja) * 2011-07-08 2016-12-07 アエゲリオン・ファーマシューティカルズ・インコーポレイテッドAegerion Pharmaceuticals, Inc. 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
WO2013009545A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity

Also Published As

Publication number Publication date
CN103547590B (zh) 2017-11-28
MX351128B (es) 2017-10-03
JP6174489B2 (ja) 2017-08-02
PT2621515T (pt) 2017-07-12
WO2012050930A3 (en) 2012-06-14
US11535659B2 (en) 2022-12-27
MX2013003482A (es) 2013-10-25
ES2641869T3 (es) 2017-11-14
JP6608799B2 (ja) 2019-11-20
JP2014502252A (ja) 2014-01-30
PT2621519T (pt) 2017-10-04
WO2012050930A2 (en) 2012-04-19
EA201390497A1 (ru) 2013-09-30
MX2013003472A (es) 2013-10-30
CY1119498T1 (el) 2018-03-07
JP2020033366A (ja) 2020-03-05
US20130203661A1 (en) 2013-08-08
DK3241558T3 (da) 2021-04-26
CA2813087A1 (en) 2012-04-19
BR112013007388A2 (pt) 2020-10-06
CA2813038C (en) 2021-12-28
BR122021020041B1 (pt) 2023-03-07
EA024507B1 (ru) 2016-09-30
EA032917B1 (ru) 2019-08-30
BR112013007385A2 (pt) 2021-04-20
EP3241558A2 (en) 2017-11-08
WO2012050925A2 (en) 2012-04-19
ES2873253T3 (es) 2021-11-03
CN103547590A (zh) 2014-01-29
JP2017141232A (ja) 2017-08-17
EP2621519B1 (en) 2017-06-28
EP2621519A4 (en) 2014-07-09
US10087228B2 (en) 2018-10-02
EP2621515A2 (en) 2013-08-07
EP2621515A4 (en) 2014-07-16
EP3305315A1 (en) 2018-04-11
US20160137709A1 (en) 2016-05-19
CA3138758A1 (en) 2012-04-19
ES2630031T3 (es) 2017-08-17
US20130274182A1 (en) 2013-10-17
EA201390474A1 (ru) 2013-07-30
WO2012050925A3 (en) 2012-07-05
US20200362006A1 (en) 2020-11-19
JP2013543497A (ja) 2013-12-05
EP2621519A2 (en) 2013-08-07
BR112013007388B1 (pt) 2022-01-04
CN103403019B (zh) 2016-10-12
DK2621515T3 (en) 2017-07-17
JP2017081939A (ja) 2017-05-18
US20160083446A1 (en) 2016-03-24
CA2813087C (en) 2020-07-21
EP2621515B1 (en) 2017-03-29
US20230115655A1 (en) 2023-04-13
EP3241558A3 (en) 2018-05-16
CN103403019A (zh) 2013-11-20
DK2621519T3 (en) 2017-10-16
MX349054B (es) 2017-07-07
EP3241558B1 (en) 2021-03-03
BR112013007385B1 (pt) 2022-07-26
CY1119023T1 (el) 2018-01-10
CA2813038A1 (en) 2012-04-19
JP6412183B2 (ja) 2018-10-24

Similar Documents

Publication Publication Date Title
EP2621515A4 (en) TOO HIGH SOLUBLE LEPTINE
AP3107A (en) 5-Alkynyl-pyrimidines
HK1182594A1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives n3--n1--5-
EP2566479A4 (en) AZA-INDAZOLES
EP2622917A4 (en) POSITIONING
EP2640189A4 (en) 3-deutero-pomalidomide
EP2622916A4 (en) POSITIONING
ZA201209117B (en) Tetrahydro-pyrido-pyrimidine derivatives
DK3466977T3 (en) Anti-vla-4-antistoffer
EP2641891A4 (en) PKC ACTIVATOR-
GB2490849B (en) Di-aspirin derivatives
HK1174625A1 (en) Pyrrazolopyridine derivatives
EP2636408A4 (en) STAMPED
EP2659886A4 (en) STAMPED
HUP1000243A2 (en) 8-hidroxy-quinoline derivatives
EP2623103A4 (en) PATCH
GB201014041D0 (en) Soluble film
AU4536P (en) TB01 Tibouchina urvilleana
AU4937P (en) FlatinsulGL Myoporum insulare
AU4932P (en) FlatwaxpinkGL Chamelaucium uncinatum
AU4931P (en) FlatwaxDarkGL Chamelaucium uncinatum
AU4822P (en) FlatwaxwhiteGL Chamelaucium uncinatum
GB201009684D0 (en) Odontalgic preparation
ZA201209248B (en) Amido-tropane derivatives
IL220983A0 (en) 2-aldoximino-5-fluoropyrimidine derivatives